Product Description
CB-020 is a iNK cell candidate for the treatment of solid tumors. (Sourced from: https://www.cariboubio.com/pipeline/)
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Caribou Biosciences
Company Location: BERKELEY CA 94710
Company CEO: Rachel E. Haurwitz
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|